Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?

Aktas, Safiye; ZENGEL, Baha; ÖZKAVRUK ELİYATKIN, NUKET

Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?

NUKET ÖZKAVRUK ELİYATKIN, (SB İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Patoloji Kliniği, İzmir, Türkiye)

Baha ZENGEL, (İzmir Bozyaka Eğitim ve Araştırma Hastanesi, 3. Genel Cerrahi Kliniği, İzmir, Türkiye)

Safiye AKTAŞ (Dokuz Eylül Üniversitesi, Onkoloji Enstitüsü, Temel Onkoloji Anabilim Dalı, İzmir, Türkiye)

Meme Sağlığı Dergisi

15 2

Yıl: 2013 Cilt: 9 Sayı: 4 Sayfa Aralığı: 175 - 181 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?

Öz:

Meme kanserlerinin yaklaşık %20’sinde, insan epidermal büyüme faktörü reseptörü-2 (HER-2) proteininin overekspresyonu ve ilişkili olduğu geninamplifikasyonu görülmektedir. HER-2 testi, meme kanserli hastaların pato- lojik değerlendirmesinde önemli bir faktördür, yalnızca prognostik değil aynızamanda hedefe yönelik tedavi seçiminde prediktif bilgi de sağlamaktadır.HER-2 proteininin ekstrasellüler bölgesine karşı geliştirilmiş bir antikor olantrastuzumab’ın, HER-2 overekspresyonu gösteren meme kanserli hastalarıntedavisinde kullanılması sağkalım sürelerini anlamlı olarak uzatmıştır. Builaçtan yarar görecek hastaların belirlenmesi optimum tedavi için gereklidir.HER-2 durumunu değerlendirmek için, birçok laboratuvarda immunohisto- kimya ve floresan in situ hibridizasyon yöntemleri kullanılmaktadır. Her ikiyöntem de bir patolog tarafından değerlendirmeyi gerektirir. Bu iki yöntem arasındaki korelasyonun %80’in altında olduğu bildirildiği gibi, laboratuvar-lar arasında standardize etmenin zorluğu ve gözlemciler arasında da değiş-kenlik nedeniyle, HER-2 mesajcı RNA (mRNA)’nın değerlendirildiği mo- leküler teknikler önerilmektedir. Daha yeni olarak, kantitatif real-time reverz transkripsiyon-PCR (Q-RT-PCR) kullanımıyla, HER-2 mRNA seviyelerininoldukça spesifik, sensitif, güvenilir ve ekonomik olarak başarılı şekilde ölçü-lebileceği bildirilmiştir. Q-RT-PCR, meme kanserinde HER-2 durumunudeğerlendirmede gelecekte seçilecek bir test olabilir. Ancak, bunun mümkünolabilmesi için, çeşitli laboratuvarların dahil edildiği çok merkezli çalışmalar ileQ-RT-PCR’ın geçerliliğinin kabul edilmesi gerekli olacaktır. Doğru HER-2 testi, hasta tedavisini iyileştirmek için gereklidir. Ancak HER-2 testinde altınstandart yoktur ve hala bu konuda optimal testin ne olması gerektiği, temelbir disiplin olarak patoloji tarafından tartışılmaktadır.

Anahtar Kelime:

Konular: Cerrahi

Meme kanserinde HER-2/NEU (C-ERB-B2) durumunun önemi: Hangi yöntemle değerlendirmek daha uygun?

Öz:

Approximately 20% of breast cancers are characterized by overexpression ofhuman epidermal growth factor receptor 2 (HER-2) protein and associatedgene amplification. HER-2 testing is an essential part of pathological assess-ment in breast cancer patients, as HER-2 provides not only prognostic butalso predictive information on the response to targeted therapy. A human-ized monoclonal antibody against the extracellular domain of HER-2 protein,trastuzumab, has significantly improved treatment outcomes in patients withHER-2-overexpressing breast cancer. Therefore, distinguishing which patientswill benefit from this drug is essential. Immunohistochemistry and fluores-cence in situ hybridization are used in many laboratories to determine HER-2status. Both methods require interpretation of the test by a pathologist. Sincethe correlation between these two methods is nearly below 80% and thesetechniques are difficult to standardize across laboratories and are subject to in-terobserver variability, molecular techniques based on the quantitative evalua-tion of HER-2 messenger RNA (mRNA) have been proposed. More recently,by using quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR), the HER2 mRNA levels have been successfully measured, making thisassay a potentially specific, highly sensitive, reliable, and cost-effective wayof measuring HER2 status. Q-RT-PCR could become the test of choice toevaluate HER2 status in breast cancer. To achieve this result, however, it willbe necessary to validate Q-RT-PCR by a multicenter trial, with the inclusionof several testing laboratories. Accurate HER2 testing is essential for qualitypatient care. However, no gold standard exists for HER2 testing, and an op-timal test for evaluation of HER2 status is still being discussed by pathology.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cance repidemiology, risk factors, and genetics. BMJ 2000; 321: 624-8. (PMID: 10977847)
2. Eser S, Olcayto E, Karakılınç H, Karaoğlanoğlu O, Yakut C, Ozalan S, ve ark. Nüfus tabanlı kanser kayıt merkezleri veri havuzu: Sekiz il, 2004- 2006 Değerlendirilmesi. http://www.kanser.gov.tr/folders/file/8iL-2006- SON.pdf
3. Schnitt SJ, Milis RR, Handy AM. The Breast in: Mills SE, Carter D, Reuter VE (Eds). Sternberg’s Diagnostic Surgical Pathology, Lippincott William &Wilkins, Philadelphia, 2004.
4. Heimann R, Hellman S. Aging, progression, and phenotype in breast can- cer. J Clin Oncol 1998; 16: 2686-92. (PMID: 9704718)
5. Rosen’s Breast Pathology, 3rd Edi. Lippincott Williams & Wilkins, Phila- delphia, 2009.
6. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognos- tic factor and target for therapy. Stem Cells 1998; 16: 413-28. (PMID: 9831867)
7. Slamon DJ, Godolphin W, Jones LA. Studies of the HER-2 / neu proto- oncogene in human breast and ovarian cancer. Science 1989; 244: 707- 12. (PMID: 2470152)
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82. (PMID: 3798106)
9. Bozzetti C, Nizzoli R, Guazzi A, Flora M, Bassano C, Crafa P, et al. HER- 2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol 2002; 13: 1398- 403. (PMID: 12196365)
10. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11: 1936-42. (PMID: 8105035)
11. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45. (PMID: 17159189)
12. Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A. De- fining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 2001; 14: 677-85. (PMID: 11455000)
13. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92. (PMID: 11248153)
14. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after ne- oadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemot- herapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676- 85. (PMID: 15738535)
15. Pierce JH, Arnstein P, Di Marco E, Artrip J, Kraus MH, Lonardo F, et al. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 1991; 6: 1189-94. (PMID: 1713661)
16. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19: 2714-21. (PMID: 11352964)
17. Onody P, Bertrand F, Muzeau F, Bièche I, Lidereau R. Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status de- termination: application to node-negative breast cancer. Arch Pathol Lab Med 2001; 125: 746-50. (PMID: 11371225)
18. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol 2000; 113: 251-8. (PMID: 10664627)
19. Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 2000; 13: 1238-43. (PMID: 11106082)
20. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carci- noma: a combined immunohistochemical and fluorescence in situ hybri- dization approach. Mod Pathol 2000; 13: 866-73. (PMID: 10955453)
21. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18. (PMID: 19548375)
22. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. J Clin Pathol 2000; 53: 374-81. (PMID: 10889820)
23. Interpretation Guideline İnform HER-2. Ventana Medical Systems, 2007, France. Available from: URL: http://www.ventana.com/ product/1553?type=2013.
24. Özdemir D, Pak I. c-erbB-2 Skor 2 Olan Meme Karsinomlarında Her -2 Amp- lifikasyonu ve Prognostik Etkinliği. Türk Patoloji Dergisi 2010; 26: 140-6.
25. Bilous M, Morey AL, Armes JE, Bell R, Button PH, Cummings MC, et al. Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program. Breast Cancer Res Treat 2012; 134: 617-24. (PMID: 22678156)
26. de Cremoux P, Martin EC, Vincent-Salomon A, Dieras V, Barbaroux C, Liva S, et al. Quantitative PCR analysis of c-erbB-2 (HER-2/neu) gene amplification and comparison with p185 (HER-2/neu) protein expressi- on in breast cancer drill biopsies. Int J Cancer 1999; 83: 157-61. (PMID: 10471520)
27. Chaudhary AG, Al-Juhani MA, Azam J, Gari M, Abuzenadah A, Al- Maghrabi, et al. Evaluation of Her-2/Neu Gene Amplification in Sau- di Female Breast Cancer Patients Using Quantitative Real-Time PCR and Fluorescence In situ Hybridisation. World Applied Sciences Journal 2011; 14: 1445-52.
28. Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, et al. Comparison of different approaches for assessment of HER2 exp- ression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat 2011: 126: 109-17.
29. Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E, Hamil- ton-Dutoit S. Real-time quantitative PCR of microdissected paraffin-em- bedded breast carcinoma: an alternative method for HER-2/neu analysis. J Mol Diagn 2004; 6: 42-51. (PMID: 14736826)
30. Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, Wlodarska I, Van- denberghe P, De Wolf-Peeters C. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology 2005; 46: 431-41. (PMID: 15810955)
31. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008; 1: 8-15. (PMID: 18437174)
32. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant tras- tuzumab in breast cancer. N Engl J Med 2008; 358: 1409-11. (PMID: 18367751)
33. Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S. Quantitative PCR and HER2 Testing in Breast Cancer (A Technical and Cost-Effectiveness Analysis). Am J Clin Pathol 2008; 129: 563-70. (PMID: 18343783)
34. Lehmann-Che J, Amira-Bouhidel F, Turpin E, Antoine M, Soliman H, Legres L, et al. Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary appro- aches. Br J Cancer 2011; 104: 1739-46. (PMID: 21540864)
35. Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targe- ting antibodies. Exp Cell Res 2010; 316: 1083-100. (PMID: 20064507)
36. Mukohara T. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci 2010; 102: 1-8. (PMID: 20825420)
37. Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anti- cancer Ther 2011: 11: 263-75. (PMID: 21342044)
38. Wong AL, Lee SC. Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer. Int J Breast Can- cer 2012: 415170. (PMID: 22649737)
39. Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, et al. Quantitati- on of p95HER2 in parafin sections by sections using a p95-spesific antibody and correlation with outcome in a cohort of trastuzumab-treated breast can- cer patients. Clin Cancer Res 2010; 16: 4226-35. (PMID: 20664024)

APA	ÖZKAVRUK ELİYATKIN N, ZENGEL B, Aktas S (2013). Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?. , 175 - 181.
Chicago	ÖZKAVRUK ELİYATKIN NUKET,ZENGEL Baha,Aktas Safiye Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?. (2013): 175 - 181.
MLA	ÖZKAVRUK ELİYATKIN NUKET,ZENGEL Baha,Aktas Safiye Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?. , 2013, ss.175 - 181.
AMA	ÖZKAVRUK ELİYATKIN N,ZENGEL B,Aktas S Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?. . 2013; 175 - 181.
Vancouver	ÖZKAVRUK ELİYATKIN N,ZENGEL B,Aktas S Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?. . 2013; 175 - 181.
IEEE	ÖZKAVRUK ELİYATKIN N,ZENGEL B,Aktas S "Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?." , ss.175 - 181, 2013.
ISNAD	ÖZKAVRUK ELİYATKIN, NUKET vd. "Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?". (2013), 175-181.

APA	ÖZKAVRUK ELİYATKIN N, ZENGEL B, Aktas S (2013). Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?. Meme Sağlığı Dergisi, 9(4), 175 - 181.
Chicago	ÖZKAVRUK ELİYATKIN NUKET,ZENGEL Baha,Aktas Safiye Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?. Meme Sağlığı Dergisi 9, no.4 (2013): 175 - 181.
MLA	ÖZKAVRUK ELİYATKIN NUKET,ZENGEL Baha,Aktas Safiye Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?. Meme Sağlığı Dergisi, vol.9, no.4, 2013, ss.175 - 181.
AMA	ÖZKAVRUK ELİYATKIN N,ZENGEL B,Aktas S Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?. Meme Sağlığı Dergisi. 2013; 9(4): 175 - 181.
Vancouver	ÖZKAVRUK ELİYATKIN N,ZENGEL B,Aktas S Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?. Meme Sağlığı Dergisi. 2013; 9(4): 175 - 181.
IEEE	ÖZKAVRUK ELİYATKIN N,ZENGEL B,Aktas S "Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?." Meme Sağlığı Dergisi, 9, ss.175 - 181, 2013.
ISNAD	ÖZKAVRUK ELİYATKIN, NUKET vd. "Importance of HER2/NEU (C-ERB-B2) status in breast cancer: Which method is more effective to evaluate of HER-2 status?". Meme Sağlığı Dergisi 9/4 (2013), 175-181.